

*Hong Kong Stock Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



**INNOCARE**

诺诚健华

**InnoCare Pharma Limited**

**諾誠健華醫藥有限公司**

*(Incorporated in the Cayman Islands with limited liability)*

**(Stock code: 9969)**

## **2023 QUARTERLY REPORT FOR THE FIRST QUARTER**

This announcement is made by InnoCare Pharma Limited (the “**Company**”) pursuant to Rules 13.09(2)(a) and 13.10B of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited and the Inside Information Provisions under Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong).

Reference is made to the “InnoCare Pharma Limited 2023 Quarterly Report for the First Quarter” (the “**2023 First Quarterly Report**”) published by the Company on the website of the Shanghai Stock Exchange, for reference purpose only. The following is a translation of the 2023 First Quarterly Report of the Company solely for the purpose of providing information. Should there be any discrepancies, the Chinese version shall prevail.

The board (the “**Board**”) of directors (the “**Directors**”) of the Company reminds shareholders and potential investors of the Company that the information and financial data set out in this announcement are unaudited, have been reviewed by the audit committee of the Company, but have not been reviewed by the independent auditors of the Company.

The unaudited financial data in the 2023 First Quarterly Report set out in this announcement is prepared in accordance with the accounting principles of the People’s Republic of China instead of the International Financial Reporting Standards, and are prepared pursuant to the requirements of the STAR Market of the Shanghai Stock Exchange only.

**Shareholders and potential investors are advised to exercise caution when dealing in securities of the Company.**

By order of the Board  
**InnoCare Pharma Limited**  
**Dr. Jisong Cui**

*Chairperson and Executive Director*

Hong Kong, 9 May 2023

*As at the date of this announcement, the Board of Directors of the Company comprises Dr. Jisong Cui as Chairperson and executive Director, Dr. Renbin Zhao as executive Director, Dr. Yigong Shi, Mr. Ronggang Xie and Mr. Ming Jin as non-executive Directors, and Dr. Zemin Jason Zhang, Ms. Lan Hu and Dr. Kaixian Chen as independent non-executive Directors.*

# 2023 FIRST QUARTERLY REPORT

Stock Code: 688428

Ticker Symbol: InnoCare

## InnoCare Pharma Limited 2023 FIRST QUARTERLY REPORT

The board of directors and all directors of the Company affirm that this announcement contains no false records or misleading statements or material omissions and that they are responsible for the truthfulness, accuracy, and completeness of its contents in accordance with the laws.

### IMPORTANT NOTICE:

The board of directors, directors and senior management of the Company undertake that the contents of the quarterly report are true, accurate, complete and without any false records, misleading statements or material omissions and are severally and jointly liable therefor.

The person in charge of the Company, person in charge of accounting function and person in charge of the Accounting Department (chief accounting officer) warrant the truthfulness, accuracy and completeness of the financial information contained in the quarterly report.

Whether the first quarterly financial statements have been audited:

Yes  No

### I. KEY FINANCIAL INFORMATION

(1) Key accounting data and financial indicators

Unit: RMB Currency: Renminbi

Items	The reporting period	Increase/decrease during the reporting period compared with the same period of the previous year (%)
Operating revenue	189,387,628.40	58.99
Among which: revenue from sales of drugs	151,370,102.78	43.46
Net profit attributable to shareholders of the listed company	-12,406,466.71	N/A
Net profit attributable to shareholders of the listed company after deducting non-recurring profits and losses	-17,474,443.66	N/A
Net cash flows generated from operating activities	-153,933,775.03	N/A

## 2023 FIRST QUARTERLY REPORT

Basic earnings per share (RMB/share)		-0.01	N/A
Diluted earnings per share (RMB/share)		-0.01	N/A
Weighted average return on equity (%)		-0.16	N/A
Total R&D expenditure		140,950,687.03	8.93
R&D expenditure as a percentage of operating revenue (%)		74.42	Decrease of 34.20 percentage points
	As at the end of the reporting period	As at the end of the previous year	Increase/decrease as at the end of the reporting period compared with the end of the previous year (%)
Total assets	10,215,914,005.30	10,328,783,979.11	-1.09
Owners' equity attributable to shareholders of the listed company	7,522,918,266.25	7,597,101,016.92	-0.98

## 2023 FIRST QUARTERLY REPORT

(2) Non-recurring profits and losses items and amounts

Unit: RMB Currency: Renminbi

Items	Amount for the reporting period	Description
Government grants included in current profits and losses (excluding those closely related to the Company's normal course of business operations and obtained constantly at a fixed amount or quantity according to a set of standards and based on the requirements of national policies)	11,137,224.44	
Gains and losses arising from changes in fair values of financial assets held for trading, derivative financial assets, financial liabilities held for trading and derivative financial liabilities, and investment income from disposal of financial assets held for trading, derivative financial assets, financial liabilities held for trading, derivative financial liabilities and other debt investments, except for effective hedging activities associated with the Company's normal course of business operations	4,566,044.57	
Other non-operating income and expenses other than the above items	612.90	
Other gains and losses classified to non-recurring profits or losses	-11,025,416.25	Note
Less: Effect on income tax		
Effect on minority interests (after tax)	-389,511.29	
Total	5,067,976.95	

Note: Other gains and losses classified to non-recurring profits or loss are losses on fair value changes of convertible borrowings issued by the Group. It is recognized as other gains or loss classified to non-recurring profits or loss due to its special nature and contingency which will affect the normal judgment of the users of the financial statements on the operation performance and profitability of the Company

Explanation on defining the non-recurring profit or loss items set out in the "Explanatory Announcement No. 1 on Information Disclosure by Companies Offering Securities to the Public — Non-recurring Profits and Losses" as recurring profit or loss items

Applicable Not applicable

## 2023 FIRST QUARTERLY REPORT

(3) Changes in key accounting data and financial indicators and the reasons therefor

√Applicable □Not applicable

Item	Percentage change (%)	Main reason
Operating revenue	58.99	It was mainly due to the increasing sales of drugs
Revenue from sales of drugs	43.46	It was mainly due to the continuing increase in sales of Orelabrutinib
Net profit attributable to shareholders of the listed company	-89.51	The decrease in net loss was due to the increase in revenue from sales of drugs on the one hand, and the increase in unrealized exchange gain resulting from the lower exchange rate of USD against RMB on the other hand
Net profit attributable to shareholders of the listed company after deducting non-recurring profits and losses	-86.96	
Basic earnings per share (RMB/share)	-87.50	On the one hand, it was due to the decrease in net loss during the reporting period; on the other hand, the number of outstanding shares increased as a result of the Company's initial public offering of shares on the STAR Market in September 2022
Diluted earnings per share (RMB/share)	-87.50	
R&D expenditure as a percentage of operating revenue (%)	-34.20	It was mainly due to the increase in operating revenue

## 2023 FIRST QUARTERLY REPORT

### II. SHAREHOLDER INFORMATION

(I) Total number of ordinary shareholders and preferred shareholders whose voting rights have been restored, and shareholdings of the top ten shareholders

1. As of the end of the reporting period, the total number of issued shares of the Company was 1,764,321,452 shares, of which 1,499,673,235 shares were issued in Hong Kong, representing approximately 85% of the total issued shares of the Company. The number of RMB shares issued on the SSE STAR Market was 264,648,217 shares, representing approximately 15% of the total issued shares of the Company.

2. The Hong Kong register of members of the Company consists of HKSCC NOMINEES LIMITED (HKSCC Nominees Limited) and other registered shareholders, of which HKSCC NOMINEES LIMITED held approximately 94.33% of the Company's Hong Kong shares on behalf of non-registered shareholders, and approximately 5.67% of the Company's Hong Kong shares were held by other registered shareholders.

3. Shares held by HKSCC NOMINEES LIMITED are held on behalf of various customers. According to the disclosure information in declaration submitted by shareholders on the Hong Kong Stock Exchange, the Company displayed the shares held by HKSCC NOMINEES LIMITED after excluding the shares held by HHLR Fund, L.P. and its persons acting in concert, King Bridge Investments Limited and its persons acting in concert, Sunny View Holdings Limited and the family of Renbin Zhao, Sunland BioMed Ltd and the family of Jisong Cui and Vivo Capital Fund VIII, L.P. and its persons acting in concert, respectively.

4. The nature of A shareholders is reported in accordance with the categories of holders in the A share register of CSDC.

Unit: share

Total number of ordinary shareholders as at the end of the reporting period	23,135	Total number of preferred shareholders whose voting rights have been restored as at the end of the reporting period (if any)	0			
Shareholdings of the top ten shareholders						
Name of shareholder	Nature of shareholder	Number of shares held	Percentage of shareholding	Number of restricted shares	Number of restricted shares (including	Pledged, marked or frozen

## 2023 FIRST QUARTERLY REPORT

			(%)	held	lending shares for refinancing)	Status of shares	Number of shares
HKSCC NOMINEES LIMITED	Unknown	725,666,837	41.13	-	-	Unknown	-
HHLR Fund,L.P. and its persons acting in concert	Overseas legal person	208,671,222	11.83	-	-	Unknown	-
King Bridge Investments Limited and its persons acting in concert	Overseas legal person	163,444,332	9.26	-	-	Unknown	-
Sunny View Holdings Limited and the family of Renbin Zhao	Overseas legal person	144,617,893	8.20	-	-	Nil	0
	Overseas natural person						
Vivo Capital Fund VIII, L.P. and its persons acting in concert	Overseas legal person	129,668,118	7.35	-	-	Unknown	-
Sunland BioMed Ltd and the family of Jisong Cui	Overseas legal person	127,589,782	7.23	-	-	Nil	0
	Overseas natural person						
Agricultural Bank of China Limited - Penghua Pharmaceutical Technology Equity Securities Investment Fund	Others	15,222,579	0.86	-	-	Nil	0
Guangzhou High-Tech Zone Technology Holding Group Co., Ltd.	State-owned legal person	8,975,521	0.51	8,975,521	8,975,521	Nil	0
Bank of China Limited - E Fund Healthcare Industry Hybrid Securities Investment Fund	Others	8,267,851	0.47	-	-	Nil	0

## 2023 FIRST QUARTERLY REPORT

China Construction Bank Corporation - ICBC Credit Suisse Frontier Medical Equity Securities Investment Fund	Others	7,000,000	0.40	-	-	Nil	0
Shareholdings of the top ten unrestricted shareholders							
Name of shareholder	Number of unrestricted outstanding shares held	Type and number of shares					
		Type	Number				
HKSCC NOMINEES LIMITED	725,666,837	Others	725,666,837				
HHLR Fund, L.P. and its persons acting in concert	208,671,222	Others	208,671,222				
King Bridge Investments Limited and its persons acting in concert	163,444,332	Others	163,444,332				
Sunny View Holdings Limited and the family of Renbin Zhao	144,617,893	Others	144,617,893				
Vivo Capital Fund VIII, L.P. and its persons acting in concert	129,668,118	Others	129,668,118				
Sunland BioMed Ltd and the family of Jisong Cui	127,589,782	Others	127,589,782				
Agricultural Bank of China Limited - Penghua Pharmaceutical Technology Equity Securities Investment Fund	15,222,579	RMB-denominated ordinary shares	15,222,579				
Bank of China Limited - E Fund Healthcare Industry Hybrid Securities Investment Fund	8,267,851	RMB-denominated ordinary shares	8,267,851				
China Construction Bank Corporation - ICBC Credit Suisse Frontier Medical Equity Securities Investment Fund	7,000,000	RMB-denominated ordinary shares	7,000,000				
China Construction Bank Corporation - Penghua Optimal Growth Hybrid Securities Investment Fund	5,839,800	RMB-denominated ordinary shares	5,839,800				



## 2023 FIRST QUARTERLY REPORT

---

Description of the connected relationships among, or concerted actions taken by the above shareholders	The Company is not aware of whether the above other shareholders have other related relationships or concerted action relationships
Description of the top ten shareholders' and the top ten unrestricted shareholders involved in margin financing and securities lending and refinancing businesses (if any)	Nil

## 2023 FIRST QUARTERLY REPORT

### III. OTHER REMINDERS

Other important information about the operation of the Company during the reporting period to which investors should pay attention

Applicable Not applicable

In July 2021, the Company entered into a collaboration and license agreement for Orelabrutinib with Biogen, under which the Company will grant the exclusive rights to Orelabrutinib in the field of MS worldwide and in the field of certain autoimmune diseases outside of China (including Hong Kong, Macau and Taiwan) to Biogen. According to the agreement, Biogen has paid a one-off, non-refundable and non-deductible upfront payment of US\$125 million to the Company.

On 15 February 2023, Biogen has notified the Company of its decision to terminate for convenience the collaboration and license agreement between them abovementioned. Following the termination, the Company will regain all global rights granted to Biogen under the agreement, including related intellectual property, decision-making power regarding research and development, manufacturing, and commercialization interests, and commercial proceeds generated from Orelabrutinib. The Company and Biogen will collaborate to complete the transition within 90 days. The Company welcomes Orelabrutinib back to its autoimmune diseases portfolio.

For a detailed overview of the business collaboration with Biogen for Orelabrutinib, please refer to the announcement of the Company disclosed on the website of the Shanghai Stock Exchange ([www.sse.com.cn](http://www.sse.com.cn)) on 16 February 2023.

### IV. QUARTERLY FINANCIAL STATEMENTS

(I) Types of audit opinions

Applicable  Not applicable

(II) Financial statements

#### Consolidated balance sheet

31 March 2023

Prepared by: InnoCare Pharma Limited

Unit: RMB Currency: Renminbi Audit type: Unaudited

Items	31 March 2023	31 December 2022
<b>Current assets:</b>		
Cash and bank balances	8,543,302,965.09	8,742,914,140.21
Clearing settlement funds		
Loans to banks and other financial institutions		
Held-for-trading financial assets		
Derivative financial assets		
Notes receivable		

## 2023 FIRST QUARTERLY REPORT

Accounts receivable	131,389,817.39	127,824,970.72
Receivables financing		
Prepayments	48,438,185.75	33,557,161.08
Premiums receivable		
Reinsurance premium receivable		
Reserves for reinsurance contract receivable		
Other receivables	3,102,412.86	4,652,782.94
Including: Interests receivable		
Dividends receivable		
Financial assets purchased under resale agreements		
Inventories	98,915,173.76	65,321,825.92
Contract assets	19,244,891.87	-
Held-for-sale assets		
Non-current assets due within one year	317,856,495.74	313,290,451.17
Other current assets	13,240,829.09	12,147,186.04
Total current assets	9,175,490,771.55	9,299,708,518.08
<b>Non-current assets:</b>		
Disbursement of loans and advances		
Debt investments		
Other debt investments		
Long-term receivables		
Long-term equity investments	11,002,915.79	11,712,050.47
Investments in other equity instruments		
Other non-current financial assets		
Investment properties		
Fixed assets	449,346,465.84	423,964,184.94
Construction in progress	194,367,138.41	197,650,071.61
Bearer biological assets		
Oil and gas assets		
Right-of-use assets	52,811,309.07	59,890,011.43
Intangible assets	270,609,834.17	273,142,788.18
Development expenses		
Goodwill	3,124,706.56	3,124,706.56
Long-term prepaid expenses	36,349,995.55	39,822,355.39
Deferred income tax assets		
Other non-current assets	22,810,868.36	19,769,292.45
Total non-current assets	1,040,423,233.75	1,029,075,461.03

## 2023 FIRST QUARTERLY REPORT

Total assets	10,215,914,005.30	10,328,783,979.11
<b>Current liabilities:</b>		
Short-term borrowings		
Borrowings from the central bank		
Loans from banks and other financial institutions		
Held-for-trading financial liabilities		
Derivative financial liabilities		
Notes payable		
Accounts payable	148,942,981.61	118,596,609.38
Receipts in advance		
Contract liabilities	-	4,241,928.28
Financial assets sold under repurchase agreements		
Deposits taking and interbank deposits		
Funds from securities trading agency		
Funds from underwriting securities agency		
Payroll payable	34,239,358.51	57,014,421.27
Taxes payable	22,022,905.56	32,580,061.43
Other payables	138,466,845.53	178,442,254.77
Including: Interests payable		
Dividends payable		
Fees and commissions payable		
Reinsured accounts payable		
Held-for-sale liabilities		
Non-current liabilities due within one year	19,265,468.90	20,111,603.34
Other current liabilities	1,673,375,992.61	1,656,685,299.66
Total current liabilities	2,036,313,552.72	2,067,672,178.13
<b>Non-current liabilities:</b>		
Reserves for insurance contracts		
Long-term borrowings		
Bonds payable		
Including: Preferred shares		
Perpetual bonds		
Lease liabilities	29,742,614.89	35,439,170.31
Long-term payables	292,049,309.45	287,761,269.12
Long-term payroll payable		
Estimated liabilities		

## 2023 FIRST QUARTERLY REPORT

Deferred income	289,487,512.13	293,584,696.08
Deferred income tax liabilities		
Other non-current liabilities		
Total non-current liabilities	611,279,436.47	616,785,135.51
Total liabilities	2,647,592,989.19	2,684,457,313.64
<b>Owners' equity (or shareholders' equity):</b>		
Paid-in capital (or share capital)	23,184.58	23,184.58
Other equity instruments		
Including: Preferred shares		
Perpetual bonds		
Capital reserve	12,106,144,404.87	12,081,647,592.34
Less: treasury shares		
Other comprehensive income	-122,584,988.07	-36,311,891.59
Special reserve		
Surplus reserve		
General risk provision		
Retained earnings	-4,460,664,335.13	-4,448,257,868.41
Total equity attributable to owners (or shareholders) of the parent company	7,522,918,266.25	7,597,101,016.92
Minority interests	45,402,749.86	47,225,648.55
Total owners' equity (or shareholders' equity)	7,568,321,016.11	7,644,326,665.47
Total liabilities and owners' equity (or shareholders' equity)	10,215,914,005.30	10,328,783,979.11

Person in charge of the Company: Jisong Cui  
 charge of the Accounting Department: Yue Tan

Person in charge of accounting function: Yue Tan

Person in

### Consolidated Statement of Income

January-March 2023

Prepared by: InnoCare Pharma Limited

Unit: RMB Currency: Renminbi Audit type: Unaudited

Items	First Quarter in 2023	First Quarter in 2022
I. Total operating revenue	189,387,628.40	119,120,479.12
Including: Operating revenue	189,387,628.40	119,120,479.12
Interest income		

## 2023 FIRST QUARTERLY REPORT

Premiums earned		
Fee and commission income		
II. Total operating costs	207,586,324.78	251,875,621.95
Including: Operating costs	42,897,028.90	28,652,737.59
Interest expenses		
Fee and commission expenses		
Surrender fee		
Net payments for insurance claims		
Net provision for deposit for insurance contracts		
Policyholder dividends		
Reinsurance premium expense		
Taxes and surcharges	2,273,281.01	1,272,158.90
Selling expenses	85,962,493.69	93,661,114.86
Administrative expenses	36,912,035.95	36,617,342.04
R&D expenses	140,950,687.03	129,396,070.62
Finance costs	-101,409,201.80	-37,723,802.06
Including: Interest expenses	10,360,573.20	1,312,050.86
Interest income	46,138,411.62	29,335,278.66
Add: Other income	11,137,224.44	21,404,364.50
Investment income (loss denoted by “-”)	-709,134.68	-3,158,651.24
Including: Share of profit of associates and joint ventures	-709,134.68	-3,237,464.55
Income from derecognition of financial assets measured at amortised cost		
Exchange gain (loss denoted by “-”)		
Net gain from hedging exposure (loss denoted by “-”)		
Gain from changes in fair value (loss denoted by “-”)	-6,459,371.68	-5,545,381.12
Credit impairment loss (loss denoted by “-”)	-	-50,858.23
Asset impairment loss (loss denoted by “-”)		
Gain on disposal of assets (loss denoted by “-”)		
III. Operating profit (loss denoted by “-”)	-14,229,978.30	-120,105,668.92
Add: Non-operating income	612.90	1,000.01
Less: Non-operating expenses	-	513,303.51
IV. Total profit (total loss denoted by “-”)	-14,229,365.40	-120,617,972.42
Less: Income tax expenses		

## 2023 FIRST QUARTERLY REPORT

V. Net profit (net loss denoted by “-”)	-14,229,365.40	-120,617,972.42
(I) By continuity of operations		
1. Net profit from continuing operations (net loss denoted by “-”)	-14,229,365.40	-120,617,972.42
2. Net profit from discontinued operations (net loss denoted by “-”)		
(II) By attribution of ownership		
1. Net profit attributable to shareholders of the parent company (net loss denoted by “-”)	-12,406,466.71	-118,242,516.18
2. Profit or loss attributable to minority shareholders (net loss denoted by “-”)	-1,822,898.69	-2,375,456.24
VI. Other comprehensive income, net of tax	-86,273,096.48	-20,492,267.89
(I) Other comprehensive income attributable to owners of the parent company, net of tax	-86,273,096.48	-20,492,267.89
1. Other comprehensive income not to be reclassified to profit or loss	-86,273,096.48	-20,492,267.89
(1) Changes in remeasurement of a defined benefit plan		
(2) Other comprehensive income not to be reclassified into profit or loss under equity method		
(3) Changes in fair value of other equity instruments investments		
(4) Changes in fair value attributable to the changes in credit risk		
(5) Translation differences of the financial statements in foreign currency	-86,273,096.48	-20,492,267.89
2. Other comprehensive income to be reclassified to profit or loss		
(1) Other comprehensive income to be reclassified to profit or loss under equity method		
(2) Changes in fair value of other debt investments		
(3) Amount of financial assets reclassified into other comprehensive income		
(4) Provision for credit impairment of other debt investments		
(5) Cash flow hedge reserve		
(6) Translation differences of the financial statements in foreign currency		
(7) Others		

## 2023 FIRST QUARTERLY REPORT

(II) Other comprehensive income attributable to minority shareholders, net of tax		
VII. Total comprehensive income	-100,502,461.88	-141,110,240.31
(I) Total comprehensive income attributable to owners of the parent company	-98,679,563.19	-138,734,784.07
(II) Total comprehensive income attributable to minority shareholders	-1,822,898.69	-2,375,456.24
VIII. Earnings per share:		
(I) Basic earnings per share (RMB/share)	-0.01	-0.08
(II) Diluted earnings per share (RMB/share)	-0.01	-0.08

For business combinations under the same control in the current period, the net profit achieved by the parties consolidated prior to the consolidation was \_RMB\_ 0.00; the net profit achieved by the parties consolidated in the previous period was \_RMB\_ 0.00 \_.

Person in charge of the Company: Jisong Cui    Person in charge of accounting function: Yue Tan    Person in charge of the Accounting Department: Yue Tan

### Consolidated Statement of Cash Flows

January-March 2023

Prepared by: InnoCare Pharma Limited

Unit: RMB    Currency: Renminbi    Audit type: Unaudited

Items	First Quarter in 2023	First Quarter in 2022
<b>I. Cash flows generated from operating activities:</b>		
Cash receipts from sales of goods and provision of services	183,364,208.30	115,504,295.38
Net increase in customer deposits and balances from banks and other financial institutions		
Net increase in borrowings from the central bank		
Net increase in funds borrowed from other financial institutions		
Cash premiums received on original insurance contracts		
Net cash received from reinsurance business		
Net increase in deposits and investments		



## 2023 FIRST QUARTERLY REPORT

from insurers		
Cash received from interests, fees and commissions		
Net increase in loans from banks and other financial institutions		
Net increase in funds for repurchase business		
Net cash received from securities trading agency		
Tax refund received		
Cash received from other operating activities	4,175,885.99	23,995,416.07
Sub-total of cash inflows from operating activities	187,540,094.29	139,499,711.45
Cash paid for goods and labour services	147,213,484.77	131,911,356.73
Net increase in customer loans and advances		
Net increase in deposits with the central bank and other financial institutions		
Cash for payment of claims under original insurance contracts		
Net increase in loans to banks and other financial institutions		
Cash paid for interests, fees and commissions		
Cash paid for policyholder dividends		
Cash paid to and on behalf of employees	146,723,558.75	117,418,720.56
Cash paid for taxes and levies	24,418,927.41	925,735.52
Cash paid for other operating activities	23,117,898.39	27,229,940.91
Sub-total of cash outflows from operating activities	341,473,869.32	277,485,753.72
Net cash flows generated from operating activities	-153,933,775.03	-137,986,042.27
<b>II. Cash flows generated from investment activities:</b>		
Cash received from the disposal of investments	26,785,935.19	25,000,000.00
Cash received from investment income	14,521,601.13	30,734,827.79

## 2023 FIRST QUARTERLY REPORT

Net cash received from the disposal of fixed assets, intangible assets and other long-term assets	-	50,442.48
Net cash received from disposal of subsidiaries and other operating entities		
Cash received from other investment activities		
Sub-total of cash inflows from investment activities	41,307,536.32	55,785,270.27
Cash paid for acquisition of fixed assets, intangible assets and other long-term assets	43,222,921.57	204,862,322.68
Cash paid for investments	-	1,464,228,174.61
Net increase in pledged loans		
Net cash paid for acquisition of subsidiaries and other operating entities		
Cash paid for other investment activities		
Sub-total of cash outflows from investment activities	43,222,921.57	1,669,090,497.29
Net cash flows generated from investing activities	-1,915,385.25	-1,613,305,227.02
<b>III. Cash flows generated from financing activities:</b>		
Cash received from capital contributions		
Including: Cash contribution to subsidiaries from minority shareholders' investment		
Cash received from borrowings		
Cash received from other financing activities		
Sub-total of cash inflows from financing activities		
Cash paid for repayment of debts		
Cash paid for distribution of dividends or profits or settlement of interest	1,009,584.20	643,274.04
Including: Dividends and profits paid by subsidiaries to minority shareholders		
Cash paid for other financing activities	8,024,532.69	7,865,208.75
Sub-total of cash outflows from financing activities	9,034,116.89	8,508,482.79

## 2023 FIRST QUARTERLY REPORT

Net cash flows generated from financing activities	-9,034,116.89	-8,508,482.79
<b>IV. Effects of changes in exchange rate on cash and cash equivalents</b>	-21,312,065.11	-11,018,532.10
<b>V. Net increase in cash and cash equivalents</b>	-186,195,342.28	-1,770,818,284.18
Add: Balance of cash and cash equivalents at the beginning of the period	4,179,983,730.99	3,237,484,305.58
<b>VI. Balance of cash and cash equivalents at the end of the period</b>	3,993,788,388.71	1,466,666,021.40

Person in charge of the Company: Jisong Cui    Person in charge of accounting function: Yue Tan    Person in charge of the Accounting Department: Yue Tan

Adjustment of the financial statements for the beginning of 2023 when the Company implements the new accounting standards or interpretation of standards for the first time

Applicable  Not applicable

The announcement is hereby made.

Board of directors of InnoCare Pharma Limited

9 May 2023